Effect of Tirzepatide on Physical Function in Postmenopausal Women With Obesity

Overview

About this study

In postmenopausal women, obesity increases the risk of physical function decline and premature aging, thus increasing the risk of vascular dysfunction and subsequent cardiovascular disease (1). Semaglutide and tirzepatide are potent antiobesity medications. Therefore, our overarching goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months)
  • Age 46-55 years old
  • BMI ≥ 30 kg/m2.

Exclusion Criteria:

  • Past or current use of menopausal hormone therapy
  • Early or premature menopause
  • History of chemically induced menopause
  • Impaired renal function (GFR ≤ 29)
  • Thyroid-stimulating hormone ≥ 7 with low free T4
  • Diabetes
  • Cardiovascular disease
  • Elevated blood pressure (> 170/> 95)
  • Uncontrolled co-morbidities including inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, or psychiatric disease
  • > 5% change in weight during the 3 months prior to screening
  • Other anti-obesity medication use within the past 3 months
  • History of bariatric surgery
  • Current use of supplements known to affect weight
  • Personal or family history of medullary thyroid cancer.
  • Wheelchair bound
  • Vision loss

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/04/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Maria Hurtado Andrade, M.D., Ph.D.

Contact us for the latest status

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available